Novartis invests €100 million to expand French manufacturing plant
pharmafile | August 15, 2016 | News story | Manufacturing and Production, Sales and Marketing | Novartis, manufacturing
Novartis has sealed the deal with construction firm Jacobs Engineering group to expand production operations at its France Center of Biotechnology facility with a €100 million investment over four years.
The facility manufactures a range of active ingredients including asthma and psoriasis treatments, anti-rejection drugs for kidney transplantation and an anti-inflammatory agent. The expansion will add a second purification line and several cell culture bioreactors to what the Swiss biopharma calls ‘the crown jewel in Novartis’ monoclonal antibody bioproduction sites for the global market.’ The new production equipment is expected to be in place by January 2017 with commercial activities starting by the end of 2018.
The decision was originally made in April to meet increasing demand for the company’s biopharmaceuticals. The expansion hopes to increase production at the facility by 70% and add 100 new jobs to the already 430-strong workforce by 2020.
Matt Fellows
Related Content
Novartis shares new data about Fabhalta for IgAN treatment
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …
Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …
Novartis shares new data for Zolgensma in children with SMA
Novartis has announced new data to continue the support of the clinical benefits of Zolgensma …